Overview
McDermott Will & Emery has advised Brenus Pharma, a biotech company specializing in the development of cancer vaccines, on its €22 million Series A fundraising.
This Series A round, led by a group of French investors in association with Belgian investment funds, will be used to finance a first Phase I/IIA clinical trial for the first candidate, STC-1010 in metastatic colorectal cancer, as well as the development of a second candidate in another solid tumor indication (STC- 1020).
The McDermott team comprised:
- Anthony Paronneau, partner, Natacha Vasak and Oriana Castelli, associates
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
